Het dopamine systeem en cognitieve achteruitgang bij patiënten met VCFS.

Dopaminergic neurotransmission and cognitive deterioration in velocardiofacial syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26307

Enrollment

Registered

2009-06-08

Start date

2009-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

velocardiofacial syndrome del22q11.2 dementia dementie velocardiofaciaal syndroom

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Deletion 22q11.2; 2. IQ < 55.

Exclusion criteria

Exclusion criteria: IQ > 55.

Design outcomes

Primary

Measure	Time frame
Catecholaminergic metabolites (in plasma: (homovanillic acid (HVA), 3-methoxybenzophenone-4 hydroxyphenethyleneglycol (MHPG), vanillylmandelic acid (VMA,) and in urine (HVA, MHPG, VMA, dopamine (free and conjugated) and norepinephrine (free and conjugated)), prolactine and proline in plasma and for COMT and PRODH polymorphism screening.	—

Secondary

Measure	Time frame
1. Vineland-S; 2. Dementiascales DMR: Dutch version: DVZ; 3. Psychiatric symptomatology: Mini PAS-ADD Behavioural scales: ABCL and SGZ.	—

Contacts

Public ContactL.J.M. Evers

rensevers@home.nl+31 (0)6 53985979

Outcome results